While therapies utilizing beta emitters like Lu-177 have made significant strides in cancer care, alpha emitters offer a new level of precision and potency.

• 
  Polonium-210 is easily produced in a reactor, and has a simple single-step alpha decay, the only nuclide with these properties
• 
  A high linear energy transfer (LET) allows for delivery of concentrated energy directly to targeted cancer cells
• 
  Efficient integration into targeted radiopharmaceuticals using established chelation chemistry

Despite their enormous potential, alpha-emitters have remained in short supply—hindering its widespread adoption. We are solving this problem.